Program
inebilizumab
Also written as “Inebilizumab”, “MEDI-551” and “MEDI-551 30 MG-IV”.
Its studies are mostly in Neuromyelitis Optica · Immunoglobulin G4-Related Disease · Myasthenia Gravis · Hepatitis, Autoimmune · Lupus Erythematosus, Systemic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 109 open or running | phase 4since Nov 17, 2023 | Nov 5, 2019 | Apr 13, 2027phase 2 · NCT05549258 |
| AstraZeneca | 70 open or running | phase 3since Jul 16, 2014 | Jul 23, 2009 | none ahead |
| Hansoh Pharmaceutical Group | 11 open or running | phase 4since Dec 15, 2023 | Dec 15, 2023 | none ahead |
| Tanabe Pharma | 11 open or running | phase 3since Jan 6, 2022 | Jan 6, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jul 23, 2009.
- Oct 1, 2013Phase 1 study in Hematologic NeoplasmsAstraZeneca · NCT01957579 · 32 enrolled · Japan
- Jul 16, 2014Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT02200770 · 231 enrolled · United States, Australia, Bulgaria and more
- Nov 5, 2019Amgen's first study: phase 2 study in Highly Sensitized Patients on Waiting List for Kidney TransplantationNew to AmgenAmgen · NCT04174677 · United States
- Aug 10, 2020Phase 3 study in Myasthenia GravisAmgen · NCT04524273 · 238 enrolled · United States, Argentina, Belarus and more
- Sep 1, 2020Phase 3 study in Immunoglobulin G4-Related DiseaseAmgen · NCT04540497 · 135 enrolled · United States, Argentina, Australia and more
- Jan 6, 2022Tanabe Pharma's first study: phase 3 study in Scleroderma, SystemicNew to Tanabe PharmaTanabe Pharma · NCT05198557 · 80 enrolled · Japan
- Jul 22, 2022Phase 2 study in Neuromyelitis OpticaAmgen · NCT05549258 · 15 planned · United States, Argentina, Brazil and more
- Nov 17, 2023Phase 4 study in Neuromyelitis OpticaAmgen · NCT06180278 · 32 enrolled · United States, China, Czechia and more
- Dec 15, 2023Hansoh Pharmaceutical Group's first study: phase 4 study in Neuromyelitis OpticaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06212245 · 33 planned · China
- Aug 22, 2024Phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798 · 220 planned · United States, Australia, Belgium and more
- May 16, 2025Phase 2 study in Myasthenia GravisAmgen · NCT06987539 · 15 planned · United States, Argentina, Brazil and more
- Oct 28, 2025Phase 2 study in Immunoglobulin G4-Related DiseaseAmgen · NCT07222553 · 15 planned · United States, Brazil, China and more
- May 14, 2026Phase 3 study in Hepatitis, AutoimmuneAmgen · NCT07598825 · 180 planned · United States, Belgium, Canada and more
- Sep 25, 2026Phase 3 study in Glomerulonephritis, MembranousAmgen · NCT07851220 · 159 planned · United States
Ahead
- Apr 13, 2027Primary completion: phase 2 study in Neuromyelitis OpticaAmgen · NCT05549258
- Jun 26, 2028Primary completion: phase 4 study in Neuromyelitis OpticaAmgen · NCT06180278
- Aug 6, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798
- Mar 13, 2030Primary completion: phase 2 study in Myasthenia GravisAmgen · NCT06987539
TargetBeta
“A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 ”NCIt, by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| rapcabtagene autoleucel | Novartis | phase 2 | 8 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07851220Glomerulonephritis, Membranous · United States | 3 | Recruiting | Amgen | Sep 27, 2031 | 159 |
| NCT07598825Hepatitis, Autoimmune · United States, Belgium, Canada and more | 3 | Recruiting | Amgen | Jul 30, 2031 | 180 |
| NCT07222553Immunoglobulin G4-Related Disease · United States, Brazil, China and more | 2 | Recruiting | Amgen | Jun 10, 2031 | 15 |
| NCT06987539Myasthenia Gravis · United States, Argentina, Brazil and more | 2 | Recruiting | Amgen | Mar 13, 2030 | 15 |
| NCT06570798Lupus Erythematosus, Systemic · United States, Australia, Belgium and more | 2 | Recruiting | Amgen | Aug 6, 2028 | 220 |
| NCT06212245Neuromyelitis Optica · China | 4 | Not yet recruiting | Hansoh Pharmaceutical Group | Dec 25, 2024 | 33 |
| NCT06180278Neuromyelitis Optica · United States, China, Czechia and more | 4 | Active, not recruiting | Amgen | Jun 26, 2028 | 32 |
| NCT05549258Neuromyelitis Optica · United States, Argentina, Brazil and more | 2 | Recruiting | Amgen | Apr 13, 2027 | 15 |
| NCT05198557Scleroderma, Systemic · Japan | 3 | Active, not recruiting | Tanabe Pharma | Jul 31, 2025 | 80 |
| NCT04540497Immunoglobulin G4-Related Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Amgen | Apr 9, 2024 | 135 |
| NCT04524273Myasthenia Gravis · United States, Argentina, Belarus and more | 3 | Active, not recruiting | Amgen | May 28, 2024 | 238 |
| NCT04174677Highly Sensitized Patients on Waiting List for Kidney Transplantation · United States | 2 | Withdrawn | Amgen | Dec 2021 | 0 |
| NCT02200770Neuromyelitis Optica · United States, Australia, Bulgaria and more | 3 | Completed | AstraZeneca | Oct 26, 2018 | 231 |
| NCT01957579Hematologic Neoplasms · Japan | 1 | Completed | AstraZeneca | Sep 15, 2015 | 32 |
| NCT01585766Multiple Sclerosis · United States, Poland, Spain and more | 1 | Completed | AstraZeneca | Jan 2, 2015 | 56 |
| NCT01453205Lymphoma, Large B-Cell, Diffuse · United States, Canada, Czechia and more | 2 | Completed | AstraZeneca | Jul 11, 2016 | 187 |
| NCT01466153Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, Canada and more | 2 | Completed | AstraZeneca | Jan 8, 2016 | 183 |
| NCT00983619Neoplasms · United States, Belgium, Canada and more | 2 | Completed | AstraZeneca | Mar 21, 2019 | 136 |
| NCT00946699Scleroderma, Diffuse · United States, Canada, United Kingdom | 1 | Completed | AstraZeneca | Mar 2012 | 50 |
How it is read
Names in the registry
- “Inebilizumab”, 12 entries
- “MEDI-551”, 7 entries
- “inebilizumab”, 1 entry
- “MEDI-551 30 MG-IV”, 1 entry
- “MEDI-551 60 MG-SC”, 1 entry
Conditions, from the studies’ own filings
- Neuromyelitis Optica, 4 studies
- Immunoglobulin G4-Related Disease, 2 studies
- Myasthenia Gravis, 2 studies
- Hepatitis, Autoimmune, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.